ARWR: Multiple late-stage RNAi programs target major unmet needs in lipid disorders, with key data ahead

The cardiometabolic pipeline leverages RNAi technology to address both rare and prevalent lipid disorders, with REDEMPLO already launched and multiple late-stage programs advancing. Key upcoming milestones include pivotal data for plozasiran and zodasiran, and first human data for the dual-targeting DIMER siRNA, all targeting significant unmet needs in hyperlipidemia and ASCVD.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.